| Stereochemistry | RACEMIC |
| Molecular Formula | C10H15NO2 |
| Molecular Weight | 181.2316 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@H](O)C1=CC=C(O)C=C1
InChI
InChIKey=OXFGTKPPFSCSMA-XVKPBYJWSA-N
InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-3-5-9(12)6-4-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1
| Molecular Formula | C10H15NO2 |
| Molecular Weight | 181.2316 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Oxilofrine is a sympathomimetic used to treat hypotensive states, with cardiac stimulatory effects similar to those of ephedrine. It has never been approved for use in the USA as a prescription drug or as a dietary supplement. Oxilofrine has been found (1) to act predominantly as a beta1 agonist increasing the speed and force of heart muscle contraction (inotropic effects), specifically, increasing left ventricular ejection fraction and stroke volume; (2) to increase blood pressure; (3) to have variable effects on heart rate; and (4) to potentially increase oxygen uptake by the lungs.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Experiments in vitro have shown oxilofrine to release noradrenaline from rat cardiac ventricular sections. This effect sets in at a concentration of 10^-5 mol/l and reaches the 30% level at 5*10^-5 mol/l. The inhibition of noradrenaline storage is still more pronounced. At 5*10^-5 mol/l the inhibition is 60%.
